Nanolattix

Nanolattix

Home page

2024.4

Release time:

2025-01-10

Nanolattix T320-ADC Successfully Selected and Signed as a 'Major Special Project' in Shanxi Province!

2024.4

Nanolattix T320-ADC Successfully Selected and Signed as a 'Major Special Project' in Shanxi Province!

Tag:

Previous Page

Next Page

Previous Page:

Next page:

recommend News

Nanolattix Announces Three Studies Selected for the ASCO 2026 Annual Meeting, Highlighting International Recognition of Innovative RDC+ADC Paradigm

2026-05-25

Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug

2025-07-09

Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies

2025-07-09

Media Focus | Tonacea: ADC Accelerates Iteration, RDC Gains Momentum – Trends at ASCO 2026 and Nanolattix‘s Strategic Logic

2026-06-02

Media Focus | Tonacea: Under the Dual-Mode Narrative, Nanolattix Launches a Synergistic Offensive

2026-04-27

Share

Nanolattix

Nanolattix

WeChat Public Number

Copyright©2024 Shanxi Nanolattix Biotechnology Co., Ltd.

Powered by 300.cn | SEO

Business License